Related Experiment Video

Updated: Aug 24, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

New targets for detection and treatment of small cell lung cancer

Nina Pedersen1, Mikkel W Pedersen, Thomas T Poulsen

  • 1Department of Radiation Biology, National University Hospital, Copenhagen, Denmark.

Chest
|May 12, 2004
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: Aug 24, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

[18F]FET PET imaging for early response assessment of bevacizumab in recurrent glioblastoma.

Neuro-oncology advances·2026

ADCE-T02 - a Next Generation Antibody Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability.

Molecular cancer therapeutics·2026

Resolving clonal evolution and selection of extrachromosomal DNA at single-cell resolution.

Genome biology·2026

Detection of fetal cfDNA in maternal blood.

Transfusion medicine (Oxford, England)·2025

The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells.

Molecular cancer therapeutics·2025

Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study.

Journal of neuro-oncology·2025

Comparing the real-world effectiveness of oral corticosteroids and antifungals for the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.

Chest·2026

Association of Antifibrotic Dosing Patterns With Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis in Real-World Data Sources.

Chest·2026

Optimization of Pharmacist Medication Management and Mortality in the Intensive Care Unit.

Chest·2026

Effect of ondansetron on respiratory drive in patients with acute respiratory distress syndrome.

Chest·2026

Comparative Short-Term Prognostic Discrimination of the 2026 AHA/ACC and 2019 ESC Risk Classifications in Hospitalized Acute Pulmonary Embolism: A Retrospective Two-Campus Cohort Study.

Chest·2026

Biological phenotypes of alveolar injury and immune failure predict mortality in non-HIV Pneumocystis jirovecii pneumonia: a Spanish multicentre cohort study.

Chest·2026

Sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis of its clinical benefit and safety.

Frontiers in medicine·2026

Nerandomilast is Associated With Altered Alveolar Epithelial Cell State Dynamics While Attenuating Fibrotic Remodeling in Pulmonary Fibrosis.

Genes to cells : devoted to molecular & cellular mechanisms·2026

Inhibition of the NR4A1-mediated cell cycle checkpoint enhances hyperplastic adipogenesis and glucose homeostasis in obesity.

British journal of pharmacology·2026

Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.

Leukemia·2026

Integrated morphological and transcriptomic analysis of bone disorders in aldosterone-salt hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension·2026

TFAM loss drives oxaliplatin resistance by linking mtDNA release to STING-TBK1-mediated lysophagy.

Oncogene·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us